Greg Wells

Greg Wells is currently a Project Lead at The University of Sheffield, where the focus is on ex-vivo drug profiling in cancer since February 2019. Prior to this role, Greg conducted research as a PhD student at the same university from November 2014 to October 2018, investigating somatic variants of the Neurofibromin 1 gene in non-small cell lung cancer and their regulation of intracellular pathways. Previous experience includes a position as a Scientist at LGC (formerly Quotient Bioresearch Ltd) from August 2013 to September 2014, and a Student role at Sheffield Hallam University, where Greg studied Biomedical Science from September 2009 to July 2013. Additionally, a Student Scientist position was held at Quotient Bioresearch Ltd from July 2011 to August 2012. Greg obtained a Doctor of Philosophy in Oncology and Cancer Biology from The University of Sheffield between 2014 and 2018, following a degree in Biomedical Science specializing in Molecular Biology from Sheffield Hallam University.